Solventum Corporation (Solventum) operates as a global healthcare company.
The company is developing, manufacturing, and commercializing a broad portfolio of solutions that leverages deep material science, data science, and digital capabilities to address critical customer and patient needs.
The company's solutions are relied on every day within the global healthcare industry to deliver higher-quality patient care, more efficient processes and workflows, and improved standards of safety and ac...
Solventum Corporation (Solventum) operates as a global healthcare company.
The company is developing, manufacturing, and commercializing a broad portfolio of solutions that leverages deep material science, data science, and digital capabilities to address critical customer and patient needs.
The company's solutions are relied on every day within the global healthcare industry to deliver higher-quality patient care, more efficient processes and workflows, and improved standards of safety and accuracy. Additionally, the company's products and services are present along a patient’s journey through prevention, diagnosis, treatment, and recovery.
The company’s business possesses strong customer relationships, a broad, wide-ranging, and well-known portfolio of brands, differentiated technology, and manufacturing expertise. The company serves a diverse customer base, ranging from multidisciplinary hospitals and local clinics/practices to biopharmaceutical manufacturers. The company’s long-tenured and collaborative customer relationships globally give it unique insights into their needs and preferences. These insights inform the company’s innovation processes, drive stronger customer retention, and create multiple avenues for further customer engagement.
## Business Segments
The company is organized into four operating business segments that are aligned with the markets it serves.
-
MedSurg
(56.2% of 2024 total sales) is a provider of solutions, including negative pressure wound therapy, advanced wound dressings, advanced skin care, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies Original Equipment Manufacturer (OEM). These solutions are designed to accelerate healing, prevent complications, and lower the total cost of care. Additionally, the company’s comprehensive range of surgical solutions are designed to mitigate a patient’s risk of infection or complications.
-
Dental Solutions
(15.7% of 2024 total sales) is a provider of a comprehensive suite of dental and orthodontic products, including brackets, aligners, restorative cements, and bonding agents that span the ‘life of the tooth,’ including products designed for preventative dental care, direct and indirect restoration, and broad orthodontic needs.
-
Health Information Systems
(15.8% of 2024 total sales) provides healthcare systems with software solutions – including computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms – that are designed to eliminate revenue cycle waste, create more time for patient care, and support value-based care. These solutions are designed to ensure accuracy of reimbursement and reduce the administrative burden that clinicians face.
-
Purification and Filtration
(11.6% of 2024 total sales) is a provider of purification and filtration technologies, including filters, purifiers, cartridges, and membranes. These solutions are designed to simplify purification processes, reduce debris and bioburden in fluids, and remove contaminants to enable the development and manufacturing of biopharmaceutical and medical technology treatments and provide cleaner water.
## Acquisitions
As part of the company’s business strategy, Solventum intends to monitor its business portfolio.
## Competition
In the MedSurg segment, the company's advanced wound care market is highly competitive, particularly in the United States and Europe, with its principal competitors, including Smith & Nephew, Medela, Mölnlycke, Coloplast, and Convatec. The company's infection prevention and surgical supplies solutions are offered in highly competitive and fragmented end markets, especially in the United States and Europe. Its principal competitors in this segment include Becton Dickinson, Hartmann, ICU Medical, Medline, Cardinal Health, Fortive, Steris, MDF Instruments, and BSN.
Principal multinational competitors within the oral care market include Dentsply Sirona, Envista, and Straumann, all of which compete with both dental and orthodontic solutions, and Ivoclar, which competes with only dental solution offerings, and Align Technology, which competes with only orthodontic solution offerings.
The health care software technology market in which the company conducts its business, and the healthcare information technology (HCIT) industry in general, is highly competitive and dynamic, characterized by the continual introduction of new products and technologies. Principal competitors include Optum, Microsoft (Nuance), Epic, Cerner, and Athena.
The Purification and Filtration segment competes against a diverse spectrum of competitors. Established global filtration competitors, such as Danaher, Merck KGaA, Sartorius, Pentair, Repligen, and Entegris, compete on a variety of factors across product lines, including breadth of offering, product performance, customer service, product availability, distribution capabilities, innovation, name recognition and price.
## Environmental, Health, and Safety Matters
Solventum is subject to extensive and evolving regulations regarding the manufacturing, processing, distribution, importing, exporting, and labeling of its products and their raw materials. In the European Union, for instance, the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) regulations came into effect in 2007. Solventum’s operations are also subject to regulation under the federal Occupational Safety and Health Act (OSHA).
Solventum manufacturing facilities are also subject to additional environmental, health and safety statutes, regulations and permit requirements, including but not limited to, applicable requirements under the Clean Air Act, the Clean Water Act, the Resource Conservation and Recovery Act, the Seveso-III Directive (Directive 2012/18/EU), the European Machinery Directive (Directive 2006/42/EC), the EU Industrial Emissions Directive (Directive 2010/75/EU), and the European Pollutant Release and Transfer Register.
## Sales and Marketing
The company has an extensive global commercial footprint with sales in over 90 countries. To serve its diverse customer base across its prioritized geographies, the company takes a multi-model commercial approach, including direct-to-customer, distribution, key account management, inside sales, and e-commerce. The company augments its commercial model with both marketing and service support. Key marketing activities include brand management, insights, price management, digital marketing, and integrated marketing communications. As its customers increasingly leverage both traditional and digital media in their path to purchase, the company continues to optimize its own omnichannel execution to ensure the best customer experience possible. The company's service support teams include clinical specialists (licensed nurses or technicians), medical liaisons (clinical professionals, such as surgeons and dentists), and application engineers (technical subject matter experts). These teams provide high-quality customer support, serving as the clinical and/or technical expert for the customer.
To expand its market coverage into emerging geographies in the Latin America (LATAM), Europe, Middle East, and Africa (EMEA), and Asia regions, the company employs an export commercial model and leverages local partners to market and sell its products. The company's local third-party partners facilitate regulatory and cross-border import compliance and distribute directly to the customer. The company’s export commercial team provides technical, clinical, and marketing support both directly to its customers, as well as to its third-party partners, to help increase customer satisfaction and support its ability to grow its global presence.
## Regulations
Solventum’s medical devices are regulated by the Food, Drug, and Cosmetic Act (FDA’s) Center for Devices and Radiological Health.
Solventum is also subject to extensive laws and regulations protecting the privacy, security, and integrity of personal information, including patient medical information, that it receives, including among others, the U.S. Health Insurance Portability and Accountability Act of 1996, as amended, (the HIPAA), the California Consumer Privacy Act (the CCPA), and similar U.S. state laws, the European Union’s General Data Protection Regulation (the E.U. GDPR), the United Kingdom’s Data Protection Act 2018 (the U.K. DPA) and the General Data Protection Regulation (the U.K. GDPR), and China’s Personal Information Protection Law (PIPL), and Personal Data Cross Border Transfer Rule (CBDT).
Solventum’s pharmaceutical products are regulated by the FDA’s Center for Drug Evaluation and Research. Solventum’s pharmaceutical products are brought to market through the NDA and OTC pathways.
Solventum’s pharmaceutical products are strictly regulated by the NMPA and various provincial, city, and county regulators.
Pursuant to Directive 2001/83/EC, advertisements of Solventum’s OTC products must, among other requirements, (1) make clear that the message is an advertisement and that the product is clearly identified as a medicinal product, (2) not refer to claims of recovery in improper, alarming or misleading terms and (3) not suggest that the effects of taking the medicine are guaranteed, are unaccompanied by adverse reactions or are better than, or equivalent to, those of another treatment or medicinal product.
In China, Solventum is subject to PIPL, which applies to the secure processing of personal information of natural persons within China, and Solventum is also subject to CBDT for the processing of personal information outside China where the purpose is to provide products and services within China and the analysis or assessment of the activities of individuals within China.
Solventum is also subject to similar privacy and data protection frameworks in other developed and emerging markets. While Solventum utilizes industry standard processes, including the National Institute of Standards and Technology (the “NIST”) privacy framework and third-party management processes, to assess the potential impact of emerging laws and enforcement trends on its business and to mitigate potential impacts on its business, data privacy laws and regulations and their scope and enforcement are constantly evolving, and Solventum cannot predict what effect, if any, changes to these laws and regulations and Solventum’s compliance with them may have on its business.
The U.S. FCPA, the U.K. Bribery Act of 2010, and similar anti-corruption and anti-bribery laws in other jurisdictions generally prohibit companies from promising to pay money or anything of value to any foreign official for the purpose of obtaining or retaining business. These laws apply to many of Solventum’s customer interactions, as healthcare professionals in other countries are or are often considered government officials, and in some cases lay out specific requirements of how to comply or demonstrate compliance with the legal requirements.
## History
Solventum Corporation was incorporated in 2023.
Das Analystenkursziel zeigt auf einen Blick die Mindest-, Höchst- und Durchschnittserwartung der Analysten.
